Ramsay (ASX:RHC) share price finishes higher as COVID surgery restrictions ease

Life is slowing moving back to normal for Ramsay.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Ramsay Health Care Ltd (ASX: RHC) share price surged throughout Wednesday. This comes as the private hospital operator provider made an important announcement to investors on the ASX.

At Wednesday's closing bell, Ramsay shares finished the day 0.81% higher to $67.29.

A patient in a hospital bed is reassured by a doctor.

Image source: Getty Images

What did Ramsay announce?

In its statement, Ramsay advised that the NSW Ministry of Health that is lifting restrictions on non-urgent elective surgery. The change is for all private and public facilities within Greater Sydney and will come into effect on 25 October.

Overnight elective surgery will be capped at 75% across the board. However, private facilities within this region can exceed the cap if they are providing surgery for public patients.

In addition, the Victorian Department of Health and Human Services also made some amendments to their policy for surgical operations. Last week, only category 1 and category 2 elective surgeries have been allowed to take place across private and public hospitals.

Day surgeries can be performed in metropolitan Melbourne. There are no current restrictions on public health services or public hospitals and emergency surgery.

While a weight has been lifted off Ramsay's shoulders, it noted there will be a material impact on its earnings for FY22. This is a result of surgical restrictions in Australia along with operating in a challenging COVID-19 environment.

About the Ramsay share price

It's been a bumpy road for Ramsay shares, navigating their way through persistent lockdowns and government-mandated restrictions. Certainly, the ASX Health Care Index (ASX: XHJ) has moved sideways since this time last year, up 1%.

When compared against the Ramsay share price, over the past 12 months, its shares have moved just 3.7% higher. However, when looking at year-to-date, its shares are up more than 8%.

Based on today's price, Ramsay commands a market capitalisation of roughly $15.4 billion and has 228.88 million shares on hand.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Ramsay Health Care Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Three businesswomen collaborate around a table.
Healthcare Shares

Clarity Pharmaceuticals reports clinical progress in June 2026 quarter

Clarity Pharmaceuticals reported $178.3 million in cash and strong clinical progress for the June 2026 quarter.

Read more »

A male doctor and a woman in scrubs in the foreground smile.
Healthcare Shares

Mesoblast FY26 earnings: Ryoncil revenue up, new trial milestones for ASX:MSB

Mesoblast reported a strong full year with US$115 million in Ryoncil revenue and advanced key clinical trials for future growth.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

CSL launches clinical trials for new plasma manufacturing process

CSL will launch clinical trials of its new Horizon 2 plasma process in 2027, seeking enhanced yields and regulatory approvals.

Read more »

A doctor in a white coat sits at her computer with finger on mouth thinking about something in her office with medical equipment in the background.
Healthcare Shares

Should I buy CSL shares before the end of July?

Here's what I expect from the beaten-down biotech stock next month.

Read more »

Concept image of a businessman riding a bull on an upwards arrow.
Broker Notes

Up 1,250% in a year, why 4DMedical shares can keep charging higher

A top analyst forecasts more outperformance from the surging shares.

Read more »

A male doctor wearing a white lab coat shrugs his shoulders and holds his hands up in the air looking confused.
Healthcare Shares

Down 31%: Is there any chance of a rebound from ResMed shares?

The ASX healthcare share has lost 31% over the past 12 months.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

If I invested $5,000 in this ASX healthcare stock 12 months ago, I'd have over $67k today!

This ASX healthcare stock is bucking the trend.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Down 35% for the year, is it time to buy this beaten-down ASX biotech?

Stronger revenue numbers signal potential upside.

Read more »